Qurient Co

Qurient Co ROA

The Return on Assets (ROA) of Qurient Co (115180.KQ) as of Nov 17, 2026 is -48.48 %. In the previous year, Return on Assets (ROA) was -35.94 % — a change of 34.89% (lower).

ROA

-48.48 %

YoY

34.89%

Last updated:

In 2025, Qurient Co's return on assets (ROA) was -48.48 %, a 34.89% increase from the -35.94 % ROA in the previous year.

The Qurient Co ROA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROA
Date
ROA
Jan 1, 2018
-38.00 KRW
Jan 1, 2019
-110.65 KRW
Jan 1, 2020
-33.71 KRW
Jan 1, 2021
-39.65 KRW
Jan 1, 2022
-66.27 KRW
Jan 1, 2023
-40.22 KRW
Jan 1, 2024
-35.94 KRW
Jan 1, 2025
-48.48 KRW
The Qurient Co ROA history
YEARROAYoY
-48.48 %+34.89%
-35.94 %-10.64%
-40.22 %-39.31%
-66.27 %+67.14%
-39.65 %+17.63%
-33.71 %-69.54%
-110.65 %+191.17%
-38.00 %-51.15%
-77.79 %+93.73%
-40.15 %-83.35%
-241.13 %+157.45%
-93.66 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Qurient Co Stock analysis

What does Qurient Co do? Qurient Co., Ltd. develops novel therapeutics with two main program phases. The development phase includes Q203 for drug-resistant tuberculosis, Q301 for atopic dermatitis, and Q701 for drug-resistant cancer and anti-cancer immunotherapy. The research phase focuses on five lipoxygenase (5LO) inhibitor asthma medicines and a cyclin dependent kinase 7 (CDK7) inhibitor cancer drug. The company generates revenue through these therapeutic programs, targeting pharmaceutical companies and healthcare providers seeking innovative treatments for resistant diseases and chronic conditions. Qurient's products are developed for specific medical needs, with Q203 addressing tuberculosis that resists standard drugs, Q301 treating skin inflammation conditions, and Q701 enhancing cancer immunotherapy. The research phase programs aim to advance asthma and cancer treatments through novel inhibitors. Pharmaceutical companies and healthcare providers purchase these therapies to address unmet medical needs in their markets. The company's revenue streams come from the development and potential commercialization of Q203, Q301, Q701, and the research phase programs. These programs target segments including tuberculosis treatment, dermatology, oncology, and respiratory diseases. Pharmaceutical firms and healthcare institutions are the primary buyers of Qurient's therapeutic solutions for drug-resistant conditions and advanced treatment options. Qurient Co is one of the most popular companies on Eulerpool.

ROA Details

Understanding Qurient Co's Return on Assets (ROA)

Qurient Co's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Qurient Co's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Qurient Co's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Qurient Co’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Qurient Co stock

Return on Assets (ROA) of Qurient Co is -48.48 % in 2025.

Return on Assets (ROA) of Qurient Co changed from -35.94 % to -48.48 %, representing a 34.89% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Assets (ROA) Qurient Co since 2006 – with annual values, charts, and detailed analysis.

Return on Assets, also known as ROA, is a financial metric used to measure a company's profitability. It is used to determine how effectively a company uses its assets to generate profits. It is also referred to as the ratio of net income to total assets. ROA is an important indicator of a company's overall financial performance as it measures the company's ability to generate more profit from the assets it employs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Assets (ROA)'s Qurient Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Assets (ROA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Assets (ROA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Qurient Co

All Key Metrics — Qurient Co